Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taro Pharmaceutical Industries Ltd.

www.taro.com

Latest From Taro Pharmaceutical Industries Ltd.

Teva And Apotex Fail To Bar Sun And Sandoz From Canadian Rivaroxaban Case

Sandoz and Sun’s Taro can be added to a pending trial over Canadian patents protecting Bayer’s Xarelto cardiovascular drug. Teva and Apotex had sought to be alone in their dispute over the rivaroxaban brand.

Intellectual Property Canada

Unsealed Price-Fixing Complaint Reveals Emails

Emails between major generics firms including Teva, Sandoz and Mylan have been revealed after a court unsealed a complaint filed by 44 US states claiming widespread price-fixing among numerous industry players.

Regulation Pricing Strategies

Deal Watch: Astellas/Cytokinetics Extend Partnership, Make Progress On SMA Candidate

The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.

Deals Business Strategies

Strongbridge Makes Case For Recorlev In First-Line Cushing's Disease

Recorlev (levoketoconazole) demonstrates efficacy and liver safety in a Phase III single-arm study, but needs to live down the bad rap of ketoconazole and ultimately escape a black box warning.

Research & Development BioPharmaceutical
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register